|
Indivior PLC on Thursday warned of a significant drop in revenue and profit for 2025, as increased competition from generic drugmakers is expected to weigh on sales of its opioid addiction treatment, Suboxone. Shares in Indivior were down 17% at 719.45 pence on Thursday afternoon in London. The Richmond, Virginia-based maker of medicines to treat substance use disorders forecast net revenue between $955 million and $1.03 billion for 2025, down 17% at the midpoint. Adjusted operating profit is expected to fall sharply to between $185 million and $225 million. Chief Executive Officer Mark Crossley said the decline is primarily due to ‘an expected decrease in Suboxone film net revenue of greater than 50% from intensified generic pricing activity along with the potential for a fifth generic entrant.’ Indivior swung to a pretax loss of $43 million for 2024, compared to a profit of $1 million the previous year, despite an 8.7% rise in net revenue to $1.19 billion from $1.09 billion. Diluted earnings per share fell to a loss of $0.36, down from earnings of $0.01 in 2023. For the three months ended December 31, net revenue edged up slightly to $298 million from $293 million. However, pretax profit declined to $31 million from $61 million, with diluted EPS for the quarter falling to $0.07 from earnings of $0.38 a year earlier. The company said it ended 2024 with a better-than-expected final quarter, driven by 20% year-on-year revenue growth in its long-acting injectable Sublocade. However, previously disclosed transitory factors and increasing competition in the US opioid treatment market weighed on overall results. Indivior said it has streamlined its cost base and identified savings exceeding $100 million, with approximately half to be reinvested in Sublocade and its pipeline for opioid use disorder treatments, while the remainder will be used to support profitability. Copyright 2025 Alliance News Ltd. All Rights reserved.
|
